STTK — Shattuck Labs, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1680367 ·
Last close
$7.07
Market Cap
$675.24M
52W High
$7.80
52W Low
$3.33
ADV30
1,660,713
Next earnings
2026-08-14
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -15,545,000 | -14,767,000 | 102,121,000 | 90,419,000 | 6,286,000 |
| Dec 2025 | 0 | — | -13,371,000 | -12,593,000 | 91,026,000 | 54,192,000 | 8,636,000 |
| Sep 2025 | 1,000,000 | — | -10,716,000 | -10,056,000 | 100,333,000 | 42,548,000 | 7,093,000 |
| Jun 2025 | 0 | — | -13,032,000 | -12,458,000 | 64,371,000 | 50,467,000 | 7,352,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-39,882,000
Investing CF
$-7,887,000
Financing CF
$44,574,000
CapEx
$-42,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.77
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-430,529,000
Inventory
—
Receivables
—
ST Investments
$23,873,000
EBIT TTM
$-51,508,000
Pretax Income TTM
$-48,809,000
Interest Exp TTM
—
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,000,000
EBITDA
$-48,940,000
Free Cash Flow
$-22,423,376
Enterprise Value
$463,802,912
Total Cash
$90,419,000
Total Debt
$2,889,000
Shares Out
95,508,165
Trailing EPS
$-0.56
Book Value
$1.27
ROE
-61.0%
ROA
-36.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,000,000 | -51,508,000 | -48,809,000 | 91,026,000 | 8,636,000 | — | -39,882,000 |
| Dec 2024 | 5,721,000 | -80,567,000 | -75,410,000 | 91,049,000 | 11,423,000 | — | -60,515,000 |
| Dec 2023 | 1,657,000 | -91,957,000 | -87,298,000 | 159,564,000 | 14,859,000 | — | -81,228,000 |
| Dec 2022 | 652,000 | -103,329,000 | -101,945,000 | 205,324,000 | 29,167,000 | — | -94,498,000 |
TTM Snapshot
Revenues TTM
$5,795,000
NetIncome TTM
$-86,261,000
OpCashFlow TTM
$0
Assets (Latest)
$91,049,000
Forward EPS
$-0.50
Max Pain — expiry 2026-12-18
max pain strike: $5.00 · spot: $7.07 · call oi: 1,597 · put oi: 2,684
Expected Move to 2026-12-18:
±$6.00
(84.87%) —
implied range
$1.07 –
$13.07
· ATM straddle on $7.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CTMX | CytomX Therapeutics, Inc. | $674.88M | $3.10 | — |
| NVCT | Nuvectis Pharma, Inc. | $678.43M | $21.52 | — |
| EVO | Evotec SE | $678.79M | $1.91 | — |
| RIGL | RIGEL PHARMACEUTICALS INC | $681.06M | $36.81 | — |
| CLYM | Climb Bio, Inc. | $681.43M | $11.90 | — |
News headlines (Yahoo Finance, 1h cache)
Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday
2026-07-24 22:27 · Yahoo
SpaceX initiated, PayPal upgraded: Wall Street's top analyst calls
2026-07-24 13:32 · Yahoo
Here Are Friday’s Top Wall Street Analyst Research Calls: Albertsons, Blue Owl Capital, Cleveland-Cliffs, Chime Financial, Digital Realty, Dover, PayPal Holdings, SpaceX, and More
2026-07-24 12:00 · Yahoo
Netflix upgraded, Microsoft initiated: Wall Street's top analyst calls
2026-07-20 13:39 · Yahoo
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
2026-06-10 04:21 · Yahoo
Shattuck Labs, Inc. Announces Proposed Public Offering
2026-06-09 20:18 · Yahoo
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
2026-06-09 12:00 · Yahoo
Shattuck Labs Announces Phase 1 Results for SL-325
2026-06-08 10:00 · Yahoo
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
2026-06-05 20:05 · Yahoo
We're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate
2026-05-11 11:33 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.